{"schema_version":"secwatch.filing_event.v1","accession":"0001459839-24-000039","form_type":"8-K","ticker":"SIBN","cik":"0001459839","company_name":"SI-BONE, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.493118+00:00","generated_at":"2026-06-02T21:55:21.970770+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SI-BONE reports Q1 revenue $37.9M (+16% YoY); raises FY2024 guidance to $164-166M","bullets":["Worldwide revenue $37.9M, up 16% YoY; U.S. revenue $35.4M, also up 16%.","Gross margin ~79%, down from ~82% due to product and procedure mix.","Net loss $10.9M ($0.27 diluted EPS) vs $11.1M ($0.32) in Q1 2023; adjusted EBITDA loss $4.0M.","FY2024 revenue guidance raised to $164-166M (18-20% growth) from $162-165M.","Surpassed 100,000 procedures; introduced smaller diameter iFuse Bedrock Granite implant."],"urls":{"canonical":"https://secwatch.observer/filing/0001459839-24-000039","json":"https://secwatch.observer/filing/0001459839-24-000039.json","markdown":"https://secwatch.observer/filing/0001459839-24-000039.md","text":"https://secwatch.observer/filing/0001459839-24-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1459839/000145983924000039/0001459839-24-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1459839/000145983924000039/sibn-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:55:21.970770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f176642aa197f9ab84ba07225fc15f4048650a1","claim":"SI-BONE, Inc. reported the quarter ended March 31, 2024 results: revenue $37.9 million, net income $10.9 million, or $0.27 per diluted share. Guidance raised.","evidence_excerpt":"reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (all comparisons are to the prior year period) • Worldwide revenue of $37.9 million, representing growth of ~16% • U.S. revenue of $35.4 million, representing growth of ~16% • Gross margin of ~79% • Over 1,100 U.S. active physicians, representing an increase of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1459839/000145983924000039/0001459839-24-000039-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$37.9 million"},{"label":"Net income","value":"$10.9 million, or $0.27 per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}